Drug class profile · refreshed daily from federal data

Typical Antipsychotic

3 molecules in this class, $44.8M combined CY2024 Part D spend across 1.4M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Typical Antipsychotic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $44.8Mcombined across class
Total Rx claims: 1.4M249K unique beneficiaries
Generic mfrs (active): 25across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Haloperidol

Brand: HALOPERIDOL · 1.4M Part D claims (CY24) · 240K beneficiaries · First FDA approval: 1986-01-14

21 generic mfrs 544 plans require PA Discontinued

Low NADAC$0.086

→

Avg plan cost$5.00

Part D spend $39.4M 58× spread, current vs floor

Class share

88%

of class CY24 spend

View profile →

Thiothixene

33K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2019-04-05

3 generic mfrs 176 plans require PA

Low NADAC$0.653

→

Avg plan cost$1.13

Part D spend $3.3M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Pimozide

16K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2015-09-28

1 generic mfrs 88 plans require PA

Low NADAC$1.23

→

Avg plan cost$1.44

Part D spend $2.1M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.